Medical treatment abroad experts

Cross-border care keeps consent, records and follow-up intact when a patient is treated in one country and monitored by clinicians at home.

1 expert, updated 22 Oct 2026

What our medical treatment abroad experts do

Cross-border care at Triple Helix Science starts with an eligibility review: a patient referred by a sovereign health system, hospital or university is assessed against the specific protocol proposed, whether that is a gene therapy, a regenerative or stem cell intervention, or a metabolic programme. Baseline measures are recorded before the patient travels. Consent is documented to cover the intervention, the handling of genomic data across two jurisdictions, and the follow-up the patient is agreeing to on return. Travel and the treatment window are scheduled around that, and the follow-up schedule is handed to a named clinician in the patient's own system.

How they work

Medical treatment abroad experts are judged on what happens after the patient flies home. Gene therapy and regenerative outcomes are read over months, so the follow-up has to be executable by a clinician who was not present at treatment, in a different health system, using measures that system can actually run. Triple Helix Science develops its protocols in house and holds them as its own intellectual property, so the people writing the consent language and specifying the follow-up are the people who designed the intervention. Because ageing is treated as systemic, follow-up tracks metabolic, cognitive and neuromuscular measures rather than the presenting condition alone.

When to bring them in

Medical treatment abroad experts are needed when a ministry, hospital group or research university is sending patients to another country for genetic, stem cell or regenerative treatment that is not yet available domestically, and the home system will carry the follow-up. They are also needed when a sovereign partner wants a cohort treated abroad before building the same capability at national scale. Triple Helix Science engages at institutional level, so a cross-border programme is commissioned by the referring health system, university or pharmaceutical partner, and depends on a named clinical counterparty in the patient's home country.

Media reaction

Preventative care and emerging health systems

"Healthcare is shifting from treating illness to preventing it, and that will transform patient outcomes and health systems alike. The biggest opportunity lies with governments in emerging economies building from scratch. Free of legacy infrastructure, they can deliver next-generation care at scale or become international hubs for treatment."
Dr Christopher JensenDr Christopher Jensen, Chief Operating Officer, Triple Helix Science20 Oct 2026

Questions about medical treatment abroad experts

The questions we get asked most about Cross-Border care, answered plainly.

What is cross-border care in medicine?
Cross-border care is the clinical, regulatory and administrative work of delivering treatment to a patient outside their home country and keeping that treatment safe and documented once the patient returns. It covers eligibility and screening before travel, consent that holds in both jurisdictions, the treatment record itself, and follow-up monitoring at home. Triple Helix Science applies it to gene therapy, stem cell and regenerative protocols delivered through sovereign health systems.
What does working with a medical treatment abroad expert actually involve?
Work starts before the patient travels, with clinical and genomic screening against the protocol's eligibility criteria and consent drafted to satisfy both the treating country's rules and the patient's home regime. Treatment is then delivered under the documented protocol, and the full record is handed to the clinicians who resume care at home. Follow-up readings return to the programme that designed the protocol.
How do you tell whether treatment abroad has been handled properly?
The test is whether the patient's home clinicians can continue care without repeating anything. The protocol, dosing and monitoring schedule should travel with the patient, consent should be valid in both jurisdictions, and follow-up data should come back to the treating programme rather than stopping at the border. Triple Helix Science treats continuity of the record and completeness of follow-up as the measure, not the procedure alone.
Is cross-border care the same as medical tourism?
No. Medical tourism brokers a procedure and the travel around it, and the relationship usually ends when the patient flies home. Cross-border care governs the clinical thread instead: eligibility, consent under two regulatory regimes, the protocol record and monitoring after return. Triple Helix Science works through governments and sovereign health systems rather than selling treatment direct to consumers, so cross-border care here is arranged at system level.
When does a health system need this, and when does it not?
Cross-border care expertise is needed when a therapy a patient requires is available in one jurisdiction and not in theirs, or when a health system plans to send a cohort abroad and wants the clinical record and follow-up to come back with them. Cross-border care is not needed where treatment and follow-up sit inside a single regulatory system and a single clinical record, which is ordinary care coordination.

Contact an expert

Get in touch with an expert on Cross-Border care for comment, an interview or a question.

Straight to the Triple Helix Science press team.